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Health state values derived from people with multiple sclerosis for a condition-specific 
preference-based measure: Multiple Sclerosis Impact Scale - Eight Dimensions – Patient 
version (MSIS-8D-P) 
 
Abstract   
 
Objective: In economic evaluation, health outcomes are commonly quantified using quality-
adjusted life-years (QALYs) derived from the preferences of a sample of the general 
population. It can be argued that this approach ignores the preferences of people with 
experience of the condition, and that patient preferences have a place in the valuation of 
health outcomes. Here we report the estimation of a preference-based index for an existing 
condition-specific preference-based measure for multiple sclerosis (MS), the MSIS-8D, based 
on the preferences of people with MS. 
 
Study design: Internet time trade-off survey, eliciting preferences from people with MS. 
 
Methods: We elicited preferences from a sample of people with MS (n=1635) across 169 
MSIS-8D health states, using the time trade-off technique. We fitted ordinary least squares 
and random effects models to the survey data to estimate values for all health states described 
by the MSIS-8D.   
 
Results: The new patient-derived index (the MSIS-8D-P) provides values ranging from 0.893 
for the best possible health state to 0.138 for the worst state. The MSIS-8D-P exhibits good 
discriminative validity, identifying expected significant differences between groups based on 
presence/absence of MS, type of MS and duration since diagnosis. 
 
Conclusions: The MSIS-8D-P index of values for MS-specific health states provides an 
opportunity to estimate QALYs based on patient preferences, for use in economic evaluations 
of treatments for MS.  More broadly, it adds to the methods and data available to consider the 
health-related quality of life of people with MS to inform resource allocation and individual-
level decisions regarding treatments for MS. 
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Highlights 
 
What is already known about the topic? 
Most commonly, the preferences that are used to estimate quality-adjusted life years 
(QALYs) are elicited from samples of the general population, rather than from people with 
the relevant health condition. 
 
What does the paper add to existing knowledge? 
This paper provides an alternative tariff of health state values for an existing preference based 
measure of health outcomes in multiple sclerosis (the MSIS-8D), based on the preferences of 
people with multiple sclerosis. 
 
What insights does the paper provide for informing health care-related decision making? 
This tariff of health state values for the MSIS-8D, based on the preferences of people with 
multiple sclerosis, can be considered alongside public preferences to provide a broader 
context for assessing the cost-effectiveness of treatments for multiple sclerosis. This paper 
also discusses wider issues concerning the common policy guidance on use of public 
preferences when undertaking economic evaluation. 
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Introduction 
 
When considering the cost effectiveness of healthcare interventions, the effects of treatment 
are frequently assessed using quality-adjusted life-years (QALYs). QALYs are calculated by 
weighting each year of life according to its quality, on a scale from 1 (equivalent to full 
health) to zero (equivalent to being dead). This combines the impact of treatment on length 
and quality of life into one measure. QALY weights are generally estimated by eliciting 
preferences between health states from a sample of the general population, or from a sample 
of people with the condition that the intervention is designed to address (hereafter referred to 
as “patients”), using a preference elicitation technique [1]. These techniques enable 
preferences to be quantified, thereby producing the quality weights, or health state values 
(HSVs), required for the calculation of QALYs [2]. QALYs are commonly based on 
preference-based measures (PBMs) of health-related quality of life (HRQL), which use a 
standardised classification system for describing health states and a tariff of quality weights 
for all health states described by the classification system. The most commonly used PBMs, 
including the Euroqol EQ-5D, are designed to be generic, ie suitable for any health condition, 
although a growing number of condition-specific PBMs are becoming available.  
 
Most commonly, preferences are elicited from members of the general population, and this 
approach is specifically recommended in most policy settings, eg by the National Institute for 
Health and Care Excellence3 and the Panel on Cost-Effectiveness in Health and Medicine 
[4,5]. However, this approach ignores the preferences of people with experience of the 
condition, and it has been argued that patient preferences have a place in the valuation of 
health [6,7]. The availability of patient preferences is all the more salient given the evidence 
of significant differences between public- and patient-derived HSVs [8]. Within a UK health 
policy context that is increasingly patient centred, with initiatives such as “No decision about 
me, without me” [9], we believe it is relevant and timely to review the role of patient 
preferences in economic evaluation. While some discussions represent a dichotomy between 
public or patient values, others suggest using values from both perspectives [4,6,7,10]. The 
common practice of reporting sensitivity analyses alongside basecase cost effectiveness 
results provides an opportunity for achieving this, in the context of reimbursement 
considerations, resource allocation decisions, and individual-level treatment decisions [8]. 
 
In previous research, we developed an MS-specific PBM, the eight dimension Multiple 
Sclerosis Impact Scale (MSIS-8D), with QALY weights based on the preferences of the UK 
general population [11]. Here, we aim to provide an alternative tariff of QALY weights for 
the MSIS-8D, based on the preferences of people with MS, for potential use across this 
spectrum of decision making. 
 
 
Materials and methods 
 
Multiple sclerosis (MS) is a chronic inflammatory condition affecting the central nervous 
system. In the majority of cases, people with MS experience exacerbations of symptoms 
(relapses) interspersed with periods of total or partial remission, before developing a 
progressive disease course. In around 10-15% of cases, the disease is progressive from onset 
[12]. Symptoms vary widely and can include physical, psychological and cognitive effects 
[13]. Here we describe the methods employed in conducting a valuation survey with a sample 
of people with MS and in undertaking analysis to estimate HSVs.  
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Health state descriptions (the MSIS-8D) 
 
Health states for MS were described using the MSIS-8D, which was developed in response to 
concerns about the content validity [13-16] and sensitivity [13, 17-19] of generic PBMs in the 
context of MS. The MSIS-8D descriptive system was derived from the Multiple Sclerosis 
Impact Scale (MSIS-29), a well validated and frequently used patient-reported outcome 
measure for MS; this is described in detail elsewhere [20]. In summary, it represents eight 
dimensions of importance to the HRQL of people with MS: physical functioning, mobility, 
social activities, daily activities, fatigue, cognitive function, emotional well-being and 
depression. The original items of the MSIS-29 were primarily based on qualitative work with 
people with MS, alongside expert opinion and a literature review [21]. The eight dimensions 
covered by the MSIS-8D descriptive system were informed by a number of previous studies 
that used qualitative techniques to explore HRQL among people with MS [20]. Each 
dimension is represented by one MSIS-29 item with four response levels: not at all, a little, 
moderately and extremely.  This constitutes a descriptive system (Figure 1) that describes 
65,536 unique MS health states.  
 
A tariff of HSVs for the MSIS-8D has been estimated previously [11]), based on preferences 
elicited from a representative sample of the UK general population for a sample of 169 
MSIS-8D health states, which was selected using the Rasch vignette approach [2] to reflect 
states that are likely to be experienced by people with MS at different levels of severity. The 
same health states are used for the current study. 
Figure 1 about here 
 
 
Valuation survey 
 
The valuation survey followed the protocol used to obtain MSIS-8D values from the general 
population, which was based on the Measurement and Valuation of Health (MVH) version of 
the time trade-off (TTO) technique. The MVH protocol was developed to generate the UK 
tariff of preference weights for the EQ-5D-3L [22,23].  Respondents are presented with a 
choice between two hypothetical scenarios: living in a suboptimal health state for a given 
number of years or living in perfect health for a shorter period of time. The length of time 
spent in perfect health is varied until the respondent is indifferent between the two scenarios. 
In this way, HSVs are determined by asking respondents to trade between quality and length 
of life [22]. The survey was administered via the internet. To ensure its suitability for the 
target population, people with MS were involved in developing the survey protocol. We used 
pre-pilot testing and an online pilot (n=55) with people with MS to finalise the valuation 
methods. 
 
Prior to undertaking the TTO tasks, participants completed the MSIS-8D descriptive system 
for their own health to familiarise themselves with the descriptive system. As warm-up 
exercises, participants were asked to rank three MSIS-8D health states in order of preference 
and to complete a practice TTO exercise with detailed instructions. Participants were then 
asked to value six MSIS-8D health states. Each set of health states was stratified to include 
five health states covering a range of severity plus the worst possible health state (the “pits” 
state). Each participant was randomly assigned a set of health states. Previous MSIS-8D 
surveys had demonstrated that this represented an acceptable workload for participants 
[11,24]; this was confirmed during pilot testing with people with MS. 
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Ethical approval was obtained from the University of Exeter Medical School Ethics 
Committee.   
 
Sample of people with MS 
 
Respondents were sourced from the UK Multiple Sclerosis Register (the MS Register).  The 
MS Register was launched in May 2011 and had 13920 members at 18th July 2016 [25]. 
Members are requested to complete a range of patient-reported outcome measures, including 
the MSIS-29, via an internet portal every three months. Other available data include socio-
demographic and clinical characteristics. Initial analysis indicates that members are broadly 
representative of people with MS in the UK in terms of key characteristics including gender, 
age at onset and MS type [26,27]. 
 
Invitation emails were circulated to all current members of the MS Register during March 
2016.  Our target sample size was 1500 respondents, in order to generate approximately 40 
observations per health state, based on a review of the literature describing the valuation of 
health states for condition-specific PBMs [28] with an adjustment to allow for the increased 
variance that may result from internet administration [29]. In previous valuation surveys, this 
was sufficient for the estimation of a regression model to predict HSVs for the MSIS-8D 
[11]. 
 
Data cleaning and descriptive analysis 
 
When estimating a tariff for a PBM, it is common practice to exclude data from respondents 
who provide responses that are internally inconsistent or illogical. This study adopted the 
exclusion criteria developed for previous MSIS-8D surveys, which were based on the 
condition-specific PBM development literature [11]. During the practice TTO exercise, 
respondents were screened out of the survey if they considered ten years in full health to be 
worse than or equivalent to ten years with health problems, or considered ten years in full 
health to be worse than or equivalent to being dead.  Following data collection, respondents 
were excluded from the analysis if they:  
 gave the same value to all health states (unless they valued all health states as 
equivalent to full health),  
 gave all states a value less than or equal to zero,  
 valued the pits state at least as highly as all other states,  
 gave the least severe state a lower value than all other states, or  
 provided three or more inconsistent responses with a difference in HSV of at least 0.1 
ie they valued a dominated health state as better than a logically better alternative by 
the equivalent of one year in the TTO exercise.   
 
Negative HSVs (ie health states considered to be worse than being dead) were transformed 
onto a scale from 0 to -1 following the method used to estimate the UK tariff for the EQ-5D-
3L [23]. 
 
Modelling to obtain health state values 
 
HSVs for all MSIS-8D health states were estimated using the standard regression model [2]:  
hij = f(β′Xλ∂) + εij  
where hij represents the TTO value; i represents individual health states; j represents 
individual respondents; f represents the functional form; X represents a vector of dummy 
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explanatory variables for each level λ of dimension ∂ of the classification system, where level 
λ = 1 acts as a baseline; and εij represents the error term. 
 
We estimated individual-level and mean-level ordinary least squares (OLS) models, fixed or 
random effects (RE) models to account for the clustering of data by respondent, and RE Tobit 
models to allow for censoring of HSV data between -0.975 and 1 [30]. Any inconsistent 
coefficients, where a less severe item-level resulted in a greater HRQL decrement than a 
more severe item-level, were merged and the analysis was re-run to produce a consistent 
model. Additional versions of these models were generated by merging adjacent item-levels 
represented by coefficients that were non-significant at the 95% level [31]. We did not 
assume that the best MSIS-8D health state represents perfect health, therefore the constant 
was not constrained to unity [28]. 
 
Models were compared in terms of the proportion of coefficients that were significant, mean 
absolute error (MAE) of predicted HSVs and the number of health states with absolute errors 
greater than 5% and 10% (equivalent to six months and one year in the TTO exercise 
respectively) [2]. This enabled selection of a preferred model to generate an index of HSVs 
for the MSIS-8D based on the preferences of people with MS. Here we do not compare the 
preferences of people with MS and those of the general public. A detailed examination of this 
comparison is reported in a companion paper [32]. 
 
Discriminative validity 
 
The sensitivity of the MSIS-8D-P index was assessed by exploring its discriminative validity 
[2]. Empirical data suggest that progressive types of MS have a greater impact on HRQL than 
relapsing-remitting MS and that the HRQL of people with MS decreases over time, therefore 
we would expect these differences to be reflected in HSVs [33,34]. Independent t-tests were 
used to determine the ability of the MSIS-8D-P index to distinguish between sub-groups of 
respondents to the valuation survey, based on type of MS and duration since diagnosis. 
Additional analysis was undertaken using MSIS-8D responses from previous surveys of the 
general population [11,24] to assess the ability of the MSIS-8D-P index to distinguish 
between people with and without MS. 
 
Analyses were undertaken using Microsoft Excel and Stata.  
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Results 
 
Valuation survey 
 
In total, 3565 members of the MS Register entered the website, of whom 1635 (46%) 
completed the survey. Of these, 39 (2.39%) provided inconsistent or illogical responses and 
were excluded from the analysis. No differences were apparent in the characteristics of 
excluded and included respondents. 
Table 1 presents the socio-demographic and clinical characteristics of the 1596 respondents 
who were included in the analysis compared to those of all MS Register members (for whom 
data was available) at the time the survey was closed. The characteristics of the survey 
respondents reflected those of the MS Register members overall in terms of age, gender, 
employment status, type and duration of MS and self-reported health status, although a higher 
proportion of respondents had a university education. Table 1 also reports respondents’ views 
of task comprehension and difficulty. The majority (84%) reported that they found the TTO 
questions easy or very easy to understand. Nearly half of respondents (47%) found it difficult 
to choose between the scenarios, but only 7% said they found this very difficult. 
 
The mean observed HSVs for the 169 health states included in the survey, presented in the 
Appendix, ranged from 0.15 for the pits state to 0.94 for the best state. The mean number of 
observations per health state was 48. The distribution of individual observed HSVs over the 
full possible range of values reflected the left skew and clustering at 0 and 1 that are typical 
of TTO data [30].   
 
The 169 health states were assigned to 24 severity groups, based on the sum of response-
levels across all dimensions [35]. The average HSV for each severity group is shown in Table 
2. The pattern is consistent with the expected direction of preferences, ie mean observed 
HSVs decrease as severity increases, with the exception of three discrepancies (group 2, 
group 4 and group 12).  
 
Modelling health state values 
The Hausman test yielded a non-significant result (chi2(24) = 14.05; p = 0.95), indicating that 
a fixed effects specification would produce a similar result with reduced efficiency, therefore 
a random effects specification was used [36]. The individual-level OLS and RE models each 
had one coefficient (corresponding to level 2 of the Fatigue dimension) with an inconsistent 
sign, and the aggregate-level OLS model produced three coefficients with an inconsistent 
sign (for Mobility levels 2 and 3 and for Fatigue level 2). Consistent versions of these models 
were created by merging the affected levels. 
Table 3 summarises the consistent individual OLS, aggregate-level OLS and RE models and 
the original Tobit model.  All models had coefficients that were consistent with expected 
preferences, ie for each dimension of the MSIS-8D, coefficient values decreased as the level 
of severity increased. The consistent individual-level OLS performed the least well, with the 
highest MAE (0.0469), number of errors over 0.1 (17) and number of errors over 0.05 (63). 
Just over one third (35%) of coefficients were significant.  
 
The consistent mean-level OLS and RE models performed similarly well. The Tobit model 
performed better in terms of significant coefficients (58.33%), however it had a slightly 
higher MAE (0.0391) and number of errors over 0.1 (7). 
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In order to avoid the loss of information that occurs when data is aggregated, the mean-level 
OLS model was not considered further. The remaining RE and Tobit models, however, had a 
relatively low proportion of significant coefficients.  Therefore, various options for merging 
affected item-levels were explored. The best-performing of these parsimonious models (RE 
Version 2 and Tobit Version 2) are presented in Table 3.  Results for all other models are 
available from the authors on request.  
 
Selection of preferred model 
 
Overall, RE Version 2 had superior predictive ability, with fewer errors >0.1 and a lower 
MAE than Tobit Version 2. On this basis, the parsimonious RE Version 2 is the 
recommended model for estimation of a single index for the MSIS-8D based on the 
preferences of people with MS.  The index ranges from 0.893 for the best MSIS-8D health 
state to 0.138 for the pits state. This indicates that respondents considered the best state to be 
less than perfect health, ie they assumed decrements in HRQL beyond the dimensions 
included in the classification system. This is not unusual for a condition-specific PBM [28]. 
 
This preferred model, as presented in Table 3, enables a HSV to be calculated for any MSIS-
8D health state, by summing the constant and the coefficient for each item depending upon its 
level. For example, the predicted value for the MSIS-8D health state (3,3,2,3,4,2,2,1) is 
calculated as: 
Constant + Physical(3) + Social(3) + Mobility(2) + Daily activities(3) + Fatigue(4) + 
Emotion(2) + Cognition(2) + Depression(1) 
= 0.893 - 0.065 - 0.032 - 0.003 - 0.020 - 0.063 - 0.015 - 0.027 + 0 = 0.668 
 
Discriminative validity 
 
Table 4 presents data describing the discriminative ability of the MSIS-8D-P. The results of 
the t-tests provided strong evidence that the index is capable of discriminating between sub-
groups of people with MS that would be expected to differ in terms of their HRQL 
(p<0.0001). Significantly lower HSVs were observed for those with progressive rather than 
relapsing-remitting MS, and for those with a disease duration of ten or more years since 
diagnosis. A large, significant difference was also observed between survey respondents with 
and without MS. 
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Discussion 
 
We have elicited preferences from people with MS to derive an alternative tariff of HSVs for 
an existing health state classification system. We refer to this as the MSIS-8D-P (Multiple 
Sclerosis Impact Scale – 8 Dimensions – People with MS). This provides an additional 
source of information about the impact of MS and its treatment on HRQL, alongside the 
original tariff of MSIS-8D values, which is based on the preferences of the general 
population. Both tariffs are suitable for use across all types of MS, to assess HRQL and to 
estimate QALYs, and can be derived directly from patient-reported responses to the MSIS-
29, a well validated and frequently used patient-reported outcome measure for MS. The 
methods employed in this study are well-accepted for the generation of HSVs for condition-
specific descriptive systems [2]. In terms of the mean absolute error and the proportion of 
health states with a prediction error greater than 0.05 or 0.1, the preferred model for the 
estimation of MSIS-8D-P values compares favourably with models that have been developed 
to estimate tariffs for other condition-specific PBMs [28]. The MSIS-8D-P exhibits good 
discriminative validity, suggesting that it is sensitive to differences and changes in the HRQL 
of people with MS. 
 
There are two potential uses for the MSIS-8D-P: providing QALY weights from the 
perspective of people with MS to inform economic evaluations and providing a source of data 
on the HRQL of people with MS to inform condition-specific resource allocation and 
individual-level treatment decisions. In addition, the availability of tariffs for the MSIS-8D 
classification system from people with MS and from the general population enables a full 
comparison to be drawn between public and patient values for MS health states. This analysis 
is reported in a companion paper. 
 
Strengths and limitations of study 
 
The results of the questions regarding self-reported task comprehension, and the nature of the 
preference data gathered, indicate that it is possible to administer a complex technique such 
as the TTO via the Internet to people with a chronic condition such as MS, which can, in 
some cases, affect cognitive functioning. The direct involvement of people with MS in 
reviewing the survey protocol, the careful construction of instructions and warm-up tasks, 
and the pre-pilot and pilot tests were instrumental in ensuring that the survey was appropriate 
for the target population. 
 
Although the approach taken in this study was informed by best practice guidance on the 
development of condition-specific PBMs [2], it has some limitations. In keeping with 
national guidelines [3], HSVs were elicited using the MVH version of the TTO. This asks 
respondents to imagine remaining in a specified health state for ten years, with no changes in 
that health state during that time.  However, MS is usually characterised by alternating 
periods of relapse and remission, or by ongoing progression [12]. This may have caused 
confusion for respondents with MS and may have affected the values they attributed to health 
states.  
 
The proportion of coefficients that were significant in the initial RE model was relatively 
small compared to other models that have been estimated to predict HSVs for condition-
specific PBMs. As a result, we merged four pairs of adjacent dimension-levels to produce the 
preferred model (along with an additional pair that was merged to address one coefficient 
with an unexpected sign, which is not unusual for models of this type) [28]. This increased 
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both the number and the proportion of coefficients that were significant. The levels that were 
merged and the coefficients that remained non-significant in the preferred model indicate that 
the preferences of people with MS were not sensitive to shifts from level 1 (not at all) to level 
2 (a little) for the Social, Mobility, Daily Activities, Emotion and Depression dimensions, or 
to shifts from level 2 (a little) to level 3 (moderately) for the Mobility, Daily Activities and 
Fatigue dimensions. 
 
Patient or public values? 
 
Two main arguments have been put forward to support the use of patient preferences in 
economic evaluation. The first rests on the theory of welfare economics, which posits that the 
well-being of a society equals the sum of the utilities of its individual members. This implies 
that it is more appropriate to base decisions regarding public programmes on the preferences 
of those set to gain or lose directly from the decision, rather than a wider sample, many of 
whom will be unaffected. The second is more prosaic: patients are likely to have more 
experience of poor health and are hence better placed to value how this affects quality of life. 
Conversely, it is argued that societal preferences should guide resource allocation in order to 
reflect the views of those who are funding the service [37], while some have expressed 
concerns that strategic bias may be introduced into HSVs if patients attempt to maximise the 
possibility of treatments being considered cost-effective [38]. Furthermore, there is debate 
over whether the differences between public and patient values represent a better 
understanding of the impact of health states by those who have experienced them, or less 
desirable effects of ill health on how people assess their situation such as distortions in HSVs 
or negative forms of adaptation (eg people failing to recognise how poor their current health 
is, what full health feels like and what it would allow them to do, or lowering their 
expectations) [10].  
 
There are arguments for and against the use of patient values to inform resource allocation 
decisions, however neither approach can claim superior theoretical or empirical validity, and 
the choice between the two is likely to affect which types of intervention are considered cost-
effective [7]. It has therefore been suggested that cost-effectiveness results based on patient 
preferences should be used in conjunction with results based on the preferences of the general 
population [4,6,7,10]. The MSIS-8D-P provides the information required to apply this 
approach in the context of MS.  
The use of condition-specific PBMs is not limited to informing the allocation of resources 
across whole healthcare systems. It has been suggested that, while public preferences are 
better suited to system-wide decision-making, patient values are more appropriate for 
informing condition-specific resource allocation and individual-level treatment decisions [4]. 
A recent systematic review of the literature describing the development of condition-specific 
PBMs [28] identified 21 instruments with tariffs based on patient preferences. Of these, 18 
were specifically designed to inform individual or clinical-level decision-making, rather than 
system-wide resource allocation. Such measures provide useful information about the factors 
that influence patients’ experiences of living with disease and that inform their decisions 
between treatment alternatives, and the relative importance of these factors. 
 
Conclusion   
 
This new tariff of HSVs for the MSIS-8D, based on the preferences of people with MS, 
provides an additional source of information to assess the impact of MS and treatments for 
people with MS, providing a broader context for resource allocation decision-making. We 
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recommend that such information should be used to determine the impact of using QALYs 
based on public preferences versus QALYs derived from preferences of those with 
experience of the condition, and to consider more broadly the common policy guidance on 
use of public preferences when undertaking economic evaluation. The MSIS-8D-P may also 
help to inform resource allocation within ring-fenced budgets for MS and individual-level 
treatment decisions.  
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Figure 1: The MSIS-8D classification system 
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Table 1: Characteristics of respondents to the preference elicitation survey 
 MSIS-8D survey 
sample 
MS Register 
members 
Characteristic Number Percentage 
Gender    
   Female 1,145 73% 72% 
   Male 424 27% 28% 
Age group    
   25 and under 7 0% 1% 
   26 to 35 85 5% 7% 
   36 to 45 304 19% 20% 
   46 to 55 504 32% 30% 
   56 to 65 463 30% 27% 
   Over 65 205 13% 15% 
Employment status    
   Economically active 633 41% 39% 
   Economically inactive 912 59% 61% 
Highest level of education    
   University 658 43% 33% 
   Occupational 464 30% 34% 
   Compulsory 298 19% 26% 
   Other 125 8% 7% 
Type of MS    
   RRMS 745 49% 51% 
   SPMS 394  26% 25% 
   PPMS 241 16% 14% 
   Benign 79 5% 5% 
   Unknown 55 4% 5% 
Time since diagnosis    
   Under 10 years 602 41% 40% 
   10 to 19 years 530 36% 36% 
   20 years and over 330 23% 24% 
Respondents’ self-reported raw scores on the MSIS-8D 
MSIS-8D total score 
   Mild (score 8-16) 441 28%  
   Moderate (score 17-24) 686 43%  
   Severe (score 25-32) 468 29%  
MSIS-8D physical score 
   Mild (score 4-8) 443 28%  
   Moderate (score 9-12) 514 32%  
   Severe (score 13-16) 638 40%  
MSIS-8D psychological score 
   Mild (score 4-8) 652 41%  
   Moderate (score 9-12) 616 39%  
   Severe (score 13-16) 327 21%  
Respondents’ self-reported task comprehension 
What were the questions like to understand? 
   Very easy 391 24.50%  
   Easy 946 59.27%  
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   Difficult 239 14.97%  
   Very difficult 20 1.25%  
How easy or difficult was it to make choices between the options you 
were asked to think about? 
   Very easy 135 8.46%  
   Easy 588 36.84%  
   Difficult 755 47.31%  
   Very difficult 118 7.39%  
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Table 2: Mean health state values by severity group 
Severity 
group 
Total 
score 
Mean SD Min Max Obs Number of 
health states 
0 8 0.943 0.150 0 1 54 1 
1 9 0.882 0.203 0 1 487 8 
2 10 0.843 0.214 0.025 1 118 3 
3 11 0.853 0.216 -0.500 1 203 4 
4 12 0.794 0.262 -0.975 1 247 5 
5 13 0.819 0.233 -0.2 1 280 6 
6 14 0.804 0.246 -0.275 1 333 7 
7 15 0.801 0.237 -0.975 1 391 8 
8 16 0.730 0.290 -0.975 1 463 9 
9 17 0.713 0.285 -0.725 1 421 10 
10 18 0.675 0.342 -0.900 1 434 10 
11 19 0.648 0.335 -0.825 1 448 10 
12 20 0.618 0.362 -0.925 1 520 11 
13 21 0.627 0.368 -0.975 1 491 10 
14 22 0.587 0.363 -0.975 1 434 9 
15 23 0.545 0.395 -0.825 1 391 8 
16 24 0.490 0.420 -0.975 1 345 8 
17 25 0.451 0.419 -0.825 1 377 8 
18 26 0.415 0.443 -0.975 1 322 7 
19 27 0.405 0.430 -0.975 1 235 6 
20 28 0.348 0.461 -0.975 1 253 5 
21 29 0.339 0.478 -0.900 1 196 4 
22 30 0.287 0.488 -0.975 1 131 3 
23 31 0.157 0.486 -0.975 1 406 8 
24 32 0.146 0.480 -0.975 1 1596 1 
SD = standard deviation; min = minimum observed value; max = 
maximum observed value; obs = observations 
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Table 3: Regression models for the estimation of health state values  
 
Consistent 
individual OLS 
Consistent  
mean OLS 
Consistent  
RE model 
Tobit model 
Preferred 
model: 
RE Version 2 
Tobit Version 2 
 
Coeff p Coeff p Coeff p Coeff p Coeff p Coeff p 
Physical 
            
A little -0.034 0.006 -0.037 0.045 -0.040 0.008 -0.072 0.000 -0.047 0.000 -0.080 0.000 
Moderately -0.036 0.082 -0.040 0.098 -0.042 0.052 -0.088 0.001 -0.065 0.000 -0.092 0.000 
Extremely -0.147 0.000 -0.151 0.000 -0.151 0.000 -0.225 0.000 -0.175 0.000 -0.230 0.000 
Social             
A little -0.022 0.173 -0.022 0.228 -0.025 0.108 -0.032 0.089  -0.037 0.030 
Moderately -0.047 0.077 -0.044 0.069 -0.051 0.027 -0.070 0.009 -0.032 0.019 -0.083 0.000 
Extremely -0.071 0.039 -0.077 0.009 -0.086 0.001 -0.115 0.000 -0.067 0.001 -0.128 0.000 
Mobility             
A little -0.001 0.935  -0.003 0.820 -0.006 0.752 -0.003 0.856 -0.006 0.716 
Moderately -0.001 0.960   -0.017 0.449 -0.019 0.462   
Extremely -0.084 0.018 -0.079 0.000 -0.092 0.001 -0.097 0.001 -0.077 0.000 -0.084 0.000 
Daily activities             
A little -0.012 0.385 -0.010 0.586 0.000 0.996 -0.009 0.629   
Moderately -0.035 0.172 -0.032 0.190 -0.013 0.568 -0.029 0.267 -0.020 0.132 -0.027 0.077 
Extremely -0.064 0.063 -0.065 0.029 -0.039 0.135 -0.053 0.084 -0.048 0.015 -0.051 0.022 
Fatigue             
A little    -0.003 0.859  -0.003 0.842 
Moderately -0.034 0.068 -0.037 0.040 -0.020 0.206 -0.033 0.184 -0.021 0.137  
Extremely -0.077 0.005 -0.086 0.001 -0.062 0.004 -0.089 0.003 -0.063 0.002 -0.060 0.010 
Emotion             
A little -0.017 0.173 -0.016 0.260 -0.016 0.187 -0.033 0.048 -0.015 0.203 -0.034 0.041 
Moderately -0.031 0.174 -0.030 0.197 -0.042 0.034 -0.060 0.014 -0.042 0.035 -0.077 0.001 
Extremely -0.049 0.165 -0.052 0.090 -0.070 0.008 -0.089 0.005 -0.069 0.009 -0.106 0.000 
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Cognition             
A little -0.027 0.054 -0.029 0.088 -0.027 0.058 -0.028 0.106 -0.027 0.030 -0.028 0.104 
Moderately -0.055 0.022 -0.053 0.033 -0.052 0.013 -0.058 0.018 -0.052 0.008 -0.057 0.019 
Extremely -0.107 0.002 -0.102 0.001 -0.115 0.000 -0.121 0.000 -0.116 0.000 -0.120 0.000 
Depression             
A little -0.006 0.706 -0.001 0.968 0.000 0.974 -0.016 0.341  -0.030 0.047 
Moderately -0.044 0.102 -0.040 0.106 -0.041 0.050 -0.065 0.006 -0.040 0.008 -0.079 0.000 
Extremely -0.166 0.000 -0.170 0.000 -0.141 0.000 -0.156 0.000 -0.140 0.000 -0.168 0.000 
Constant 0.902 0.000 0.902 0.000 0.894 0.000 1.089 0.000 0.893 0.000 1.092 0.000 
Model 
performance 
      
Coefficients 23 22 23 24 19 21 
Sig coefficients 8 (34.78%) 10 (47.62%) 11 (47.83%) 14 (58.33%) 15 (78.95%) 17 (80.95%) 
Mean absolute 
error 
0.0469 0.0349 0.0361 0.0391 0.0364 0.0399 
No of errors > 0.1 17 2 2 7 3 8 
No of errors > 0.05 63 46 50 49 52 51 
Obs (respondents) 9576 (1596) 169 (1596) 9576 (1596) 9576 (1596) 9576 (1596) 9576 (1596) 
Wald chi2 NA NA 8897.14 (23) 9305.22 (24) 8893.62 (19) 9300.19 (21) 
Prob > chi2  NA NA <0.001 <0.001 <0.001 <0.001 <0.001 
Overall R-sq NA NA 0.3014 NA 0.3013 NA 
Log likelihood NA NA NA -3846.31 NA NA 
F 185.91 (24, 9551) 133.94 (21, 147) NA NA NA NA 
Prob>F <0.001 <0.001 NA NA NA NA 
R-sq 0.3017 0.9503 NA NA NA NA 
Adj R-sq NA 0.9432 NA NA NA NA 
RMSE 0.3767 0.0469 NA NA NA NA 
 
 43 
 
Table 4: Discriminative validity of the MSIS-8D-P 
  Mean SD Frequency t-statistic p-value 
Disease status No MS 0.766 0.172 3490 28.931 <0.0001 
 MS 0.613 0.186 1635   
Duration of 
MS 
Under 10 yrs 0.645 0.187 612 4.943 <0.0001 
 
10 yrs or 
over 
0.597 0.182 882 
  
MS type Relapsing 0.666 0.177 760 -12.651 <0.0001 
 Progressive 0.547 0.175 652   
SD = standard deviation 
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